CTMX Stock Price, Chart, Stats & News
CTMX chart
Fundamentals
Gross margin | 99.33% |
Operating margin | -29.35% |
Pretax margin | -22.48% |
Net margin | -22.79% |
Effective tax rate | -1.38% |
ROA | -11.39% |
ROE | -19.77% |
D/E | 0.04x |
Interest coverage ratio | – |
CTMX valuation
P/E | – |
P/S | 10.10x |
P/B | 7.77x |
P/CF | -10.18x |
P/FCF | -10.15x |
P/OCF | -10.18x |
PEG | 0.45x |
EV multiple | -40.12x |
About
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.
Similar securities
Based on sector and market capitalization
